Page last updated: 2024-11-05

triflupromazine and Parkinson Disease, Secondary

triflupromazine has been researched along with Parkinson Disease, Secondary in 1 studies

Triflupromazine: A phenothiazine used as an antipsychotic agent and as an antiemetic.
triflupromazine : A member of the class of phenothiazines that is 10H-phenothiazine having a trifluoromethyl subsitituent at the 2-position and a 3-(dimethylamino)propyl group at the N-10 position.

Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Maickel, RP1
Braunstein, MC1
McGlynn, M1
Snodgrass, WR1
Webb, RW1

Other Studies

1 other study available for triflupromazine and Parkinson Disease, Secondary

ArticleYear
Behavioral, biochemical, and pharmacological effects of chronic dosage of phenothiazine tranquilizers in rats.
    Advances in biochemical psychopharmacology, 1974, Volume: 9, Issue:0

    Topics: Animals; Avoidance Learning; Behavior, Animal; Body Weight; Brain Chemistry; Chlorpromazine; Dose-Re

1974